Regulation of BIRC5 and its isoform BIRC5-2B in neuroblastoma

Cancer Letters

Volumn 285, Issue 1, 2009, Pages 99-107

  Eckerle, Isabella ^a   Muth, Daniel ^a   Batzler, Julia ^a   Henrich, Kai Oliver ^a   Lutz, Werner ^b   Fischer, Matthias ^c   Witt, Olaf ^d   Schwab, Manfred ^a   Westermann, Frank ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

BIRC5; BIRC5 2B; E2F1; MYCN; Neuroblastoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ONCOPROTEIN; PROTEIN BIRC5 2B; PROTEIN MYCN; S PHASE KINASE ASSOCIATED PROTEIN 2; SMALL INTERFERING RNA; SURVIVIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; CELL LINE, TUMOR; CYCLIN B; CYCLIN-DEPENDENT KINASE INHIBITOR P21; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; RNA INTERFERENCE; RNA, MESSENGER; S-PHASE KINASE-ASSOCIATED PROTEINS; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 70349301395     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.05.007     Document Type: Article

References (35)

1. Berthold F., and Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 59 (2000) 1261-1277
2. Schwab M., Alitalo K., Klempnauer K.H., Varmus H.E., Bishop J.M., Gilbert F., Brodeur G., Goldstein M., and Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305 (1983) 245-248
3. Brodeur G.M., Seeger R.C., Schwab M., Varmus H.E., and Bishop J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224 (1984) 1121-1124
4. Mahotka C., Wenzel M., Springer E., Gabbert H.E., and Gerharz C.D. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 59 (1999) 6097-6102
5. Plantaz D., Mohapatra G., Matthay K.K., Pellarin M., Seeger R.C., and Feuerstein B.G. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am. J. Pathol. 150 (1997) 81-89
6. Jiang Y., Saavedra H.I., Holloway M.P., Leone G., and Altura R.A. Aberrant regulation of survivin by the RB/E2F family of proteins. J. Biol. Chem. 279 (2004) 40511-40520
7. Mirza A., McGuirk M., Hockenberry T.N., Wu Q., Ashar H., Black S., Wen S.F., Wang L., Kirschmeier P., Bishop W.R., Nielsen L.L., Pickett C.B., and Liu S. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21 (2002) 2613-2622
8. Hoffman W.H., Biade S., Zilfou J.T., Chen J., and Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 277 (2002) 3247-3257
9. Lohr K., Moritz C., Contente A., and Dobbelstein M. p21/CDKN1A mediates negative regulation of transcription by p53. J. Biol. Chem. 278 (2003) 32507-32516
10. O'Connor D.S., Grossman D., Plescia J., Li F., Zhang H., Villa A., Tognin S., Marchisio P.C., and Altieri D.C. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. USA 97 (2000) 13103-13107
11. Shin S., Sung B.J., Cho Y.S., Kim H.J., Ha N.C., Hwang J.I., Chung C.W., Jung Y.K., and Oh B.H. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40 (2001) 1117-1123
12. Casciano I., Banelli B., Croce M., De Ambrosis A., di Vinci A., Gelvi I., Pagnan G., Brignole C., Allemanni G., Ferrini S., Ponzoni M., and Romani M. Caspase-8 gene expression in neuroblastoma. Ann. NY Acad. Sci. 1028 (2004) 157-167
13. Spitz R., Hero B., Ernestus K., and Berthold F. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Med. Pediatr. Oncol. 41 (2003) 30-35
14. London W.B., Boni L., Simon T., Berthold F., Twist C., Schmidt M.L., Castleberry R.P., Matthay K.K., Cohn S.L., and De Bernardi B. The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. Cancer Lett. 228 (2005) 257-266
15. Berthold F., Sahin K., Hero B., Christiansen H., Gehring M., Harms D., Horz S., Lampert F., Schwab M., and Terpe J. The current contribution of molecular factors to risk estimation in neuroblastoma patients. Eur. J. Cancer 33 (1997) 2092-2097
16. Lutz W., Stohr M., Schurmann J., Wenzel A., Lohr A., and Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13 (1996) 803-812
17. Kramps C., Strieder V., Sapetschnig A., Suske G., and Lutz W. E2F and Sp1/Sp3 synergize but are not sufficient to activate the MYCN gene in neuroblastomas. J. Biol. Chem. 279 (2004) 5110-5117
18. Wiedemeyer R., Westermann F., Wittke I., Nowock J., and Schwab M. Ataxin-2 promotes apoptosis of human neuroblastoma cells. Oncogene 22 (2003) 401-411
19. Fischer M., Skowron M., and Berthold F. Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. J. Mol. Diagn. 7 (2005) 89-96
20. Westermann F., Muth D., Benner A., Bauer T., Henrich K.O., Oberthuer A., Brors B., Beissbarth T., Vandesompele J., Pattyn F., Hero B., Konig R., Fischer M., and Schwab M. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol. 9 (2008) R150
21. Wu S., Cetinkaya C., Munoz-Alonso M.J., von der Lehr N., Bahram F., Beuger V., Eilers M., Leon J., and Larsson L.G. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 22 (2003) 351-360
22. Sagulenko V., Muth D., Sagulenko E., Paffhausen T., Schwab M., and Westermann F. Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death. Carcinogenesis 29 (2008) 1869-1877
23. Westermann F., Henrich K.O., Wei J.S., Lutz W., Fischer M., Konig R., Wiedemeyer R., Ehemann V., Brors B., Ernestus K., Leuschner I., Benner A., Khan J., and Schwab M. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status. Clin. Cancer Res. 13 (2007) 4695-4703
24. Henrich K.O., Fischer M., Mertens D., Benner A., Wiedemeyer R., Brors B., Oberthuer A., Berthold F., Wei J.S., Khan J., Schwab M., and Westermann F. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin. Cancer Res. 12 (2006) 131-138
25. D. Muth, S. Ghazaryan, I. Eckerle, E. Beckett, C. Pöhler, J. Batzler, C. Beisel, M. Fischer, K.O. Henrich, V. Ehemann, M. Schwab, F. Westermann, Transcriptional Repression of SKP2 is Impaired in MYCN-Amplified Neuroblastoma, submitted for publication.
26. Bornstein G., Bloom J., Sitry-Shevah D., Nakayama K., Pagano M., and Hershko A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J. Biol. Chem. 278 (2003) 25752-25757
27. Carrano A.C., Eytan E., Hershko A., and Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell. Biol. 1 (1999) 193-199
28. Taubert H., Kappler M., Bache M., Bartel F., Kohler T., Lautenschlager C., Blumke K., Wurl P., Schmidt H., Meye A., and Hauptmann S. Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene 24 (2005) 5258-5261
29. Islam A., Kageyama H., Takada N., Kawamoto T., Takayasu H., Isogai E., Ohira M., Hashizume K., Kobayashi H., Kaneko Y., and Nakagawara A. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19 (2000) 617-623
30. Ling X., Cheng Q., Black J.D., and Li F. Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin. J. Biol. Chem. 282 (2007) 27204-27214
31. Radhakrishnan S.K., Feliciano C.S., Najmabadi F., Haegebarth A., Kandel E.S., Tyner A.L., and Gartel A.L. Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle. Oncogene 23 (2004) 4173-4176
32. Kip1 Expression by E2F1. A negative feedback mechanism. J. Biol. Chem. 280 (2005) 12339-12343
33. Herold S., Wanzel M., Beuger V., Frohme C., Beul D., Hillukkala T., Syvaoja J., Saluz H.P., Haenel F., and Eilers M. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol. Cell 10 (2002) 509-521
34. Seoane J., Le H.V., and Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419 (2002) 729-734
35. Jung P., Menssen A., Mayr D., and Hermeking H. AP4 encodes a c-MYC-inducible repressor of p21. Proc. Natl. Acad. Sci. USA 105 (2008) 15046-15051